Abstract:Temozolomide (TMZ) is considered a standard chemotherapeutic agent for glioblastoma (GBM). Characterizing the biological molecules and signaling pathways involved in TMZ sensitivity would be helpful for selecting therapeutic schemes and evaluating prognosis for GBM. Thus, in the present study, we selected 34 glioma cell lines paired with specific IC50 values of TMZ obtained from CancerRxGene and RNA-seq data downloaded from the Cancer Cell Line Encyclopedia to identify genes related to TMZ sensitivity. The results showed that 1,373 genes were related to the response of GBM cells to TMZ. Biological function analysis indicated that epithelial–mesenchymal transition, Wnt signaling, and immune response were the most significantly activated functions in TMZ-resistant cell lines. Additionally, negative regulation of telomere maintenance via telomerase was enriched in TMZ-sensitive glioma cell lines. We also preliminarily observed a synergistic effect of combination treatment comprising TMZ and a telomerase inhibitor in vitro. We identified six genes (MROH8, BET1, PTPRN2, STC1, NKX3-1, and ARMC10) using the random survival forests variable hunting algorithm based on the minimum error rate of the gene combination and constructed a gene expression signature. The signature was strongly related to GBM clinical characteristics and exhibited good prognosis accuracy for both The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) datasets. Patients in the high score group had a shorter survival time than those in the low score group (11.2 vs. 22.2 months, hazard ratio = 7.31, p = 4.59e−11) of the TCGA dataset. The CGGA dataset was selected as a validation group with 40 patients in the high score set and 43 patients in the low score set (12.5 vs. 28.8 months, hazard ratio = 3.42, p = 8.61e−5). Moreover, the signature showed a better prognostic value than MGMT promoter methylation in both datasets. We also developed a nomogram for clinical use that integrated the TMZ response signature and four other risk factors to individually predict patient survival after TMZ chemotherapy. Overall, our study provides promising therapeutic targets and potential guidance for adjuvant therapy of GBM.

Case report: Temozolomide induced hypermutation: an indicator associated with immunotherapy response in patient with gliomas

Hypermutagenesis In Untreated Adult Gliomas Due To Inherited Mismatch Mutations

Path-30. Clinical Outcomes And Predictive Biomarkers For Idh-Wildtype Glioblastomas Developing Hypermutation Following Temozolomide Treatment

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

MYC amplification at diagnosis drives therapy-induced hypermutation of recurrent glioma

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma

Mechanisms and therapeutic implications of hypermutation in gliomas

Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas

Temozolomide Chemotherapy Based on MGMT Protein Expression for Patients with Malignant Gliomas:A Report of 40 Cases

Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma

[Individualized Chemotherapy Based on Drug Sensitivity and Resistance Assay and MGMT Protein Expression for Patients with Malignant Glioma--analysis of 42 Cases].

Multi-Omics Analyses Reveal Mitochondrial Dysfunction Contributing to Temozolomide Resistance in Glioblastoma Cells

Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide

Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?

The role of trimethylation on histone H3 lysine 27 (H3K27me3) in temozolomide resistance of glioma

Mutations in the PIK3C2B, ERBB3, KIT, and MLH1 Genes and Their Relationship with Resistance to Temozolomide in Patients with High-Grade Gliomas

Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications